These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 32517881

  • 21. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea.
    Seok JM, Cho HJ, Ahn SW, Cho EB, Park MS, Joo IS, Shin HY, Kim SY, Kim BJ, Kim JK, Cho JY, Huh SY, Kwon O, Lee KH, Kim BJ, Min JH.
    Mult Scler; 2017 Nov; 23(13):1748-1756. PubMed ID: 28058965
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. The expansion of circulating IL-6 and IL-17-secreting follicular helper T cells is associated with neurological disabilities in neuromyelitis optica spectrum disorders.
    Monteiro C, Fernandes G, Kasahara TM, Barros PO, Dias ASO, Araújo ACRA, Ornelas AMM, Aguiar RS, Alvarenga R, Bento CAM.
    J Neuroimmunol; 2019 May 15; 330():12-18. PubMed ID: 30769212
    [Abstract] [Full Text] [Related]

  • 24. Serum 25-hydroxyvitamin D3 is associated with disease status in patients with neuromyelitis optica spectrum disorders in south China.
    Shan Y, Tan S, Zhang L, Huang J, Sun X, Wang Y, Cai W, Qiu W, Hu X, Lu Z.
    J Neuroimmunol; 2016 Oct 15; 299():118-123. PubMed ID: 27725109
    [Abstract] [Full Text] [Related]

  • 25. Serum Creatine Kinase in Patients with Neuromyelitis Optica Spectrum Disorder.
    Shouman K, Prieto PG, Stino AM, Lisak RP.
    J Neuroimmunol; 2019 May 15; 330():87-89. PubMed ID: 30851543
    [Abstract] [Full Text] [Related]

  • 26. Association Between Serum Interleukin-32 Level and Disease Status in Cases with Neuromyelitis Optica Spectrum Disorders.
    Yu HF, Xu J, Fang Y, Xiao LC.
    J Inflamm Res; 2024 May 15; 17():5645-5652. PubMed ID: 39219816
    [Abstract] [Full Text] [Related]

  • 27. Serum albumin level is associated with the severity of neurological dysfunction of NMOSD patients.
    Yao XY, Wu YF, Gao MC, Hong RH, Ding J, Hao Y, Zhang Y, Guan YT.
    Mult Scler Relat Disord; 2020 Aug 15; 43():102130. PubMed ID: 32417662
    [Abstract] [Full Text] [Related]

  • 28. Markedly increased IP-10 production by blood-brain barrier in neuromyelitis optica.
    Shimizu F, Nishihara H, Sano Y, Takeshita Y, Takahashi S, Maeda T, Takahashi T, Abe M, Koga M, Kanda T.
    PLoS One; 2015 Aug 15; 10(3):e0122000. PubMed ID: 25811465
    [Abstract] [Full Text] [Related]

  • 29. Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes.
    Alves Do Rego C, Collongues N.
    Rev Neurol (Paris); 2018 Jun 15; 174(6):458-470. PubMed ID: 29685427
    [Abstract] [Full Text] [Related]

  • 30. Regulatory T cells protect against brain damage by alleviating inflammatory response in neuromyelitis optica spectrum disorder.
    Ma X, Qin C, Chen M, Yu HH, Chu YH, Chen TJ, Bosco DB, Wu LJ, Bu BT, Wang W, Tian DS.
    J Neuroinflammation; 2021 Sep 15; 18(1):201. PubMed ID: 34526069
    [Abstract] [Full Text] [Related]

  • 31. Serum levels of cell adhesion molecules in patients with neuromyelitis optica spectrum disorder.
    Chang BL, Ro LS, Chen CM, Lo YS, Lyu RK, Kuo HC, Liao MF, Chang CW, Chang HS, Huang CC, Wu YR, Chu CC, Weng YC, Chang KH.
    Ann Clin Transl Neurol; 2020 Oct 15; 7(10):1854-1861. PubMed ID: 32860355
    [Abstract] [Full Text] [Related]

  • 32. [Clinical characteristics and follow-up of pediatric patients with neuromyelitis optica and neuromyelitis optica spectrum disorders].
    Yun W, Weihua Z, Xiaotun R, Jiuwei L, Xinying Y, Junlan L, Changhong D, Chunhong C, Haitao R, Liying C, Fang F.
    Zhonghua Er Ke Za Zhi; 2015 Apr 15; 53(4):268-73. PubMed ID: 26182501
    [Abstract] [Full Text] [Related]

  • 33. Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica.
    Wilson R, Makuch M, Kienzler AK, Varley J, Taylor J, Woodhall M, Palace J, Leite MI, Waters P, Irani SR.
    Brain; 2018 Apr 01; 141(4):1063-1074. PubMed ID: 29447335
    [Abstract] [Full Text] [Related]

  • 34. Association of serum Cystatin C with neuromyelitis optica spectrum disorders.
    Shu Y, Zhang L, Chang Y, Li R, Sun X, Li J, Wu H, Yang Y, Peng L, Lu Z, Kermode AG, Qiu W.
    Eur J Neurol; 2018 Jul 01; 25(7):999-1002. PubMed ID: 29603501
    [Abstract] [Full Text] [Related]

  • 35. Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort.
    Carnero Contentti E, Daccach Marques V, Soto de Castillo I, Tkachuk V, Ariel B, Castillo MC, Cristiano E, Diégues Serva GB, Dos Santos AC, Finkelsteyn AM, López PA, Patrucco L, Molina O, Pettinicchi JP, Toneguzzo V, Caride A, Rojas JI.
    J Neurol; 2020 May 01; 267(5):1260-1268. PubMed ID: 31932911
    [Abstract] [Full Text] [Related]

  • 36. Blood sphingolipid as a novel biomarker in patients with neuromyelitis optica spectrum disorder.
    Kim H, Kim HJ, So J, Kim JY, Jung HJ, Kim S, Seo D, Kim HJ, Song HE, Lim YM, Yoo HJ, Lee EJ.
    Mult Scler Relat Disord; 2024 May 01; 85():105551. PubMed ID: 38564996
    [Abstract] [Full Text] [Related]

  • 37. Plasma Homocysteine Level Is Associated with the Expanded Disability Status Scale in Neuromyelitis Optica Spectrum Disorder.
    Liang J, Liu J, Fan R, Chen Z, Chen X, Tong J, Chen Y, Peng F, Jiang Y.
    Neuroimmunomodulation; 2019 May 01; 26(5):258-264. PubMed ID: 31655825
    [Abstract] [Full Text] [Related]

  • 38. Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis.
    Keller A, Leidinger P, Meese E, Haas J, Backes C, Rasche L, Behrens JR, Pfuhl C, Wakonig K, Gieß RM, Jarius S, Meder B, Bellmann-Strobl J, Paul F, Pache FC, Ruprecht K.
    J Neuroinflammation; 2015 Oct 31; 12():196. PubMed ID: 26521232
    [Abstract] [Full Text] [Related]

  • 39. The IL-10-producing regulatory B cells (B10 cells) and regulatory T cell subsets in neuromyelitis optica spectrum disorder.
    Cho EB, Cho HJ, Seok JM, Min JH, Kang ES, Kim BJ.
    Neurol Sci; 2018 Mar 31; 39(3):543-549. PubMed ID: 29349658
    [Abstract] [Full Text] [Related]

  • 40. Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases.
    Lee EJ, Lim YM, Kim S, Choi L, Kim H, Kim K, Kim HW, Lee JS, Kim KK.
    Ann Clin Transl Neurol; 2020 Jun 31; 7(6):992-1001. PubMed ID: 32495489
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.